Literature DB >> 9882373

CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains.

S Genoud1, F Kajumo, Y Guo, D Thompson, T Dragic.   

Abstract

The human immunodeficiency virus type 1 coreceptor activity of CCR5 depends on certain polar and charged residues in its amino-terminal domain. Since studies of chimeric receptors have indicated that the extracellular loops of CCR5 are also involved in viral fusion and entry, we have explored the role of bulky, polar and nonpolar residues in these regions. Selected amino acids in the three extracellular loops were individually changed to alanines, and the coreceptor activities of the mutant CCR5 proteins were tested in a luciferase reporter virus-based entry assay. We found that the cysteines in the extracellular loops of CCR5 are essential for coreceptor activity. However, only minor (two- to threefold) effects on coreceptor function were noted for all of the other alanine substitutions. We also demonstrated that when the first 19 residues of the amino-terminal region were separated from the rest of CCR5, by insertion of glycine/serine spacers between proline 19 and cysteine 20, coreceptor function decreased. Together with our previous studies, these data indicate that both an amino-terminal gp120-binding site and extracellular domain geometry play a role in viral entry.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882373      PMCID: PMC103992     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.

Authors:  Y J Zhang; T Dragic; Y Cao; L Kostrikis; D S Kwon; D R Littman; V N KewalRamani; J P Moore
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

2.  Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity.

Authors:  J Rucker; M Samson; B J Doranz; F Libert; J F Berson; Y Yi; R J Smyth; R G Collman; C C Broder; G Vassart; R W Doms; M Parmentier
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

3.  Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

Authors:  R E Atchison; J Gosling; F S Monteclaro; C Franci; L Digilio; I F Charo; M A Goldsmith
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

Review 4.  Molecular properties of the chemokine receptor family.

Authors:  R Horuk
Journal:  Trends Pharmacol Sci       Date:  1994-05       Impact factor: 14.819

5.  Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene.

Authors:  Y Takeuchi; M Akutsu; K Murayama; N Shimizu; H Hoshino
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

7.  Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.

Authors:  G Simmons; D Wilkinson; J D Reeves; M T Dittmar; S Beddows; J Weber; G Carnegie; U Desselberger; P W Gray; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells.

Authors:  B Chesebro; R Buller; J Portis; K Wehrly
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

9.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

View more
  14 in total

1.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

Authors:  M Germana Paterlini
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

2.  Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Authors:  A Trkola; T J Ketas; K A Nagashima; L Zhao; T Cilliers; L Morris; J P Moore; P J Maddon; W C Olson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Authors:  W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Frequent substitution polymorphisms in African green monkey CCR5 cluster at critical sites for infections by simian immunodeficiency virus SIVagm, implying ancient virus-host coevolution.

Authors:  S E Kuhmann; N Madani; O M Diop; E J Platt; J Morvan; M C Müller-Trutwin; F Barré-Sinoussi; D Kabat
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1.

Authors:  S E Kuhmann; E J Platt; S L Kozak; D Kabat
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies.

Authors:  Shuqun Liu; Shixiu Fan; Zhirong Sun
Journal:  J Mol Model       Date:  2003-08-29       Impact factor: 1.810

7.  Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.

Authors:  Samvel R Mkrtchyan; Ruben M Markosyan; Michael T Eadon; John P Moore; Gregory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.

Authors:  Robert A Ogert; Lei Ba; Yan Hou; Catherine Buontempo; Ping Qiu; Jose Duca; Nicholas Murgolo; Peter Buontempo; Robert Ralston; John A Howe
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

9.  Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

Authors:  Fotini Tsamis; Svetlana Gavrilov; Francis Kajumo; Christoph Seibert; Shawn Kuhmann; Tom Ketas; Alexandra Trkola; Anadan Palani; John W Clader; Jayaram R Tagat; Stuart McCombie; Bahige Baroudy; John P Moore; Thomas P Sakmar; Tatjana Dragic
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

10.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Authors:  Reem Berro; Rogier W Sanders; Min Lu; Per J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.